Clinical Trial Update: Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety and efficacy of sintilimab (a PD-1 inhibitor) in combination with metformin for small-cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Sintilimab (sintilimab)
• metformin (metformin)

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Small-cell Lung Cancer, Small Cell Lung Carcinoma | Phase 2 | Status: UNKNOWN